跳转至内容
Merck

Y0000364

氯碘羟喹

European Pharmacopoeia (EP) Reference Standard

别名:

5-氯-7-碘-8-羟基喹啉, 5-氯-8-羟基-7-碘喹啉, 氯碘喹啉, 氯碘羟喹

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C9H5ClINO
CAS号:
分子量:
305.50
Beilstein:
153637
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

clioquinol

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

Oc1c(I)cc(Cl)c2cccnc12

InChI

1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H

InChI 密鑰

QCDFBFJGMNKBDO-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Clioquinol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Skull and crossbones

訊號詞

Danger

危險分類

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

A D Schimmer
Current cancer drug targets, 11(3), 325-331 (2011-01-21)
Clioquinol (5-chloro-7-iodo-quinolin-8-ol) was used in the 1950's-1970's as an oral anti-parasitic agent. More recently, studies have demonstrated that Clioquinol displays preclinical efficacy in the treatment of malignancy. Its anti-cancer activity relates, at least in part, to its ability to inhibit
Kouichi Yoshinari et al.
Toxicology letters, 206(2), 229-233 (2011-08-09)
Clioquinol, originally marketed as an oral intestinal amebicide, was widely used for multiple intestinal disorders. Its use as an oral agent was, however, discontinued because of its possible association with subacute myelo-optico-neuropathy or SMON. Meanwhile, its use for neurodegenerative diseases
Aaron D Schimmer et al.
Clinical lymphoma, myeloma & leukemia, 12(5), 330-336 (2012-06-12)
Clioquinol is a small-molecule metal ionophore that inhibits the proteasome through a metal-dependent mechanism. Here, we report a phase I study of clioquinol in patients with refractory hematologic malignancies. Neuropathy and abdominal pain were dose-limiting toxicities. Minimal pharmacodynamic effects were
Tao Wang et al.
Journal of Alzheimer's disease : JAD, 29(3), 549-559 (2012-01-25)
Metal dyshomeostasis in the brain helps promote amyloid-β (Aβ) deposition in Alzheimer's disease (AD). Therefore, targeting the interactions between metal and Aβ is a potential therapeutic approach for AD. The metal chelator, clioquinol (CQ), is thought to reduce Aβ deposits
Masato Katsuyama et al.
Toxicology, 299(1), 55-59 (2012-05-26)
Clioquinol, a Cu²⁺/Zn²⁺/Fe²⁺ chelator/ionophor, was used extensively in the mid 1900s as an amebicide for treating indigestion and diarrhea. It was eventually withdrawn from the market because of a link to subacute myelo-optic neuropathy (SMON) in Japan. The pathogenesis of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门